Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment

Science Translational Medicine

Volumn 8, Issue 329, 2016, Pages

  Wang, Suming ^a,b   Blois, Anna ^a,b,c   El Rayes, Tina ^d   Liu, Joyce F ^b,e   Hirsch, Michelle S ^b   Gravdal, Karsten ^c,f   Palakurthi, Sangeetha ^e   Bielenberg, Diane R ^a,b   Akslen, Lars A ^c,f   Drapkin, Ronny ^b,e,g   Mittal, Vivek ^d   Watnick, Randolph S ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD36 ANTIGEN; CISPLATIN; PROSAPOSIN PEPTIDE; PROTEIN P53; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; AMINO ACID; CYCLOPEPTIDE; SPHINGOLIPID ACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG EFFICACY; DRUG SCREENING; DRUG STABILITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; C57BL MOUSE; CANCER GRADING; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; REGRESSION ANALYSIS; SECONDARY; TISSUE MICROARRAY; TUMOR CELL LINE;

AMINO ACIDS; ANIMALS; ANTIGENS, CD36; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIZATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE, INBRED C57BL; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PEPTIDES, CYCLIC; REGRESSION ANALYSIS; SAPOSINS; THROMBOSPONDIN 1; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960463647     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad5653     Document Type: Article

References (39)

1. A. M. Karst, R. Drapkin, Ovarian cancer pathogenesis: A model in evolution. J. Oncol. 2010, 932371 (2010).
2. L. Dubeau, R. Drapkin, Coming into focus: The nonovarian origins of ovarian cancer. Ann. Oncol. 24(Suppl. 8), viii28-viii35 (2013).
3. B. W. Stewart, C. P. Wild, World Cancer Report 2014 (WHO Press, Geneva, 2014).
4. K. Matsuo, V. K. Bond, M. L. Eno, D. D. Im, N. B. Rosenshein, Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int. J. Cancer 125, 2721-2727 (2009).
5. K. Matsuo, M. L. Eno, D. D. Im, N. B. Rosenshein, A. K. Sood, Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol. Oncol. 116, 61-65 (2010).
6. R. Catena, N. Bhattacharya, T. El Rayes, S. Wang, H. Choi, D. Gao, S. Ryu, N. Joshi, D. Bielenberg, S. B. Lee, S. A. Haukaas, K. Gravdal, O. J. Halvorsen, L. A. Akslen, R. S. Watnick, V. Mittal, Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578-589 (2013).
7. S.-Y. Kang, O. J. Halvorsen, K. Gravdal, N. Bhattacharya, J. M. Lee, N. W. Liu, B. T. Johnston, A. B. Johnston, S. A. Haukaas, K. Aamodt, S. Yoo, L. A. Akslen, R. S. Watnick, Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc. Natl. Acad. Sci. U. S. A. 106, 12115-12120 (2009).
8. D. J. Good, P. J. Polverini, F. Rastinejad, M. M. Le Beau, R. S. Lemons, W. A. Frazier, N. P. Bouck, A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U. S. A. 87, 6624-6628 (1990).
9. J. Lawler, W.-M. Miao, M. Duquette, N. Bouck, R. T. Bronson, R. O. Hynes, Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am. J. Pathol. 159, 1949-1956 (2001).
10. W.-M. Miao, W. Lin Seng, M. Duquette, P. Lawler, C. Laus, J. Lawler, Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factorbdependent and -independent mechanisms. Cancer Res. 61, 7830-7839 (2001).
11. R. N. Kaplan, R. D. Riba, S. Zacharoulis, A. H. Bramley, L. Vincent, C. Costa, D. D. MacDonald, D. K. Jin, K. Shido, S. A. Kerns, Z. Zhu, D. Hicklin, Y. Wu, J. L. Port, N. Altorki, E. R. Port, D. Ruggero, S. V. Shmelkov, K. K. Jensen, S. Rafii, D. Lyden, VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).
12. D. W. Dawson, S. F. A. Pearce, R. Zhong, R. L. Silverstein, W. A. Frazier, N. P. Bouck, CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138, 707-717 (1997).
13. S. Russell, M. Duquette, J. Liu, R. Drapkin, J. Lawler, J. Petrik, Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer. FASEB J. 29, 576-588 (2014).
14. V. Bobde, Y. U. Sasidhar, S. Durani, Harnessing D-amino acids for peptide motif designs. synthesis and solution conformation of Boc-D-Glu-Ala-Gly-Lys-NHMe and Boc-L-Glu-Ala-Gly-Lys-NHMe. Int. J. Pept. Protein Res. 43, 209-218 (1994).
15. M. Coltrera, M. Rosenblatt, J. T. Potts Jr., Analogues of parathyroid hormone containing Damino acids: Evaluation of biological activity and stability. Biochemistry 19, 4380-4385 (1980).
16. A. S. Dutta, M. B. Giles, Polypeptides. Part XIV. A comparative study of the stability towards enzymes of model tripeptides containing a-aza-amino-acids, L-amino-acids, and D-amino-acids. J. Chem. Soc. Perkin 1, 244-248 (1976).
17. A. G. Lamont, M. F. Powell, S. M. Colón, C. Miles, H. M. Grey, A. Sette, The use of peptide analogs with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo. J. Immunol. 144, 2493-2498 (1990).
18. M. F. Powell, T. Stewart, L. Otvos Jr., L. Urge, F. C. A. Gaeta, A. Sette, T. Arrhenius, D. Thomson, K. Soda, S. M. Colon, Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm. Res. 10, 1268-1273 (1993).
19. J. Greenaway, J. Henkin, J. Lawler, R. Moorehead, J. Petrik, ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol. Cancer Ther. 8, 64-74 (2009).
20. J. J. Petrik, P. A. Gentry, J.-J. Feige, J. LaMarre, Expression and localization of thrombospondin-1 and -2 and their cell-surface receptor, CD36, during rat follicular development and formation of the corpus luteum. Biol. Reprod. 67, 1522-1531 (2002).
21. K. Li, M. Yang, P. M. P. Yuen, K. W. Chik, C. K. Li, M. Ming, K. Shing, H. K. B. Lam, T. F. Fok, Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and caspase-3. Int. J. Mol. Med. 12, 995-1001 (2003).
22. N. Campbell, J. Greenaway, J. Henkin, J. Petrik, ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer. Mol. Cancer Ther. 10, 1876-1885 (2011).
23. G. Martin-Manso, S. Galli, L. A. Ridnour, M. Tsokos, D. A. Wink, D. D. Roberts, Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res. 68, 7090-7099 (2008).
24. A. Clauss, V. Ng, J. Liu, H. Piao, M. Russo, N. Vena, Q. Sheng, M. S. Hirsch, T. Bonome, U. Matulonis, A. H. Ligon, M. J. Birrer, R. Drapkin, Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kB pathway and is associated with poor overall survival. Neoplasia 12, 161-172 (2010).
25. S. Ghamande, B. L. Hylander, E. Oflazoglu, S. Lele, W. Fanslow, E. A. Repasky, Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 61, 7556-7562 (2001).
26. S. J. Bogdanowich-Knipp, S. Chakrabarti, T. D. Williams, R. K. Dillman, T. J. Siahaan, Solution stability of linear vs. cyclic RGD peptides. J. Pept. Res. 53, 530-541 (1999).
27. H. Iwai, A. Plückthun, Circular b-lactamase: Stability enhancement by cyclizing the backbone. FEBS Lett. 459, 166-172 (1999).
28. A. X. Ji, M. Bodanszky, Cyclization studies with a model pentapeptide. Int. J. Pept. Protein Res. 22, 590-596 (1983).
29. J. Møss, H. Bundgaard, Kinetics and mechanism of the facile cyclization of histidylprolineamide to cyclo (His-Pro) in aqueous solution and the competitive influence of human plasma. J. Pharm. Pharmacol. 42, 7-12 (1990).
30. J. Samanen, F. Ali, T. Romoff, R. Calvo, E. Sorenson, J. Vasko, B. Storer, D. Berry, D. Bennett, Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J. Med. Chem. 34, 3114-3125 (1991).
31. J. F. Liu, M. S. Hirsch, H. Lee, U. A. Matulonis, Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol. Oncol. 115, 401-406 (2009).
32. P. Burger, P. Hilarius-Stokman, D. de Korte, T. K. van den Berg, R. van Bruggen, CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 119, 5512-5521 (2012).
33. A. Saumet, M. B. Slimane, M. Lanotte, J. Lawler, V. Dubernard, Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/avb3 in promyelocytic leukemia NB4 cells. Blood 106, 658-667 (2005).
34. N. A. Abumrad, M. R. el-Maghrabi, E. Z. Amri, E. Lopez, P. A. Grimaldi, Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J. Biol. Chem. 268, 17665-17668 (1993).
35. C. M. Harmon, N. A. Abumrad, Binding of sulfosuccinimidyl fatty acids to adipocyte membrane proteins: Isolation and amino-terminal sequence of an 88-kD protein implicated in transport of long-chain fatty acids. J. Membr. Biol. 133, 43-49 (1993).
36. S. Pradeep, S. W. Kim, S. Y. Wu, M. Nishimura, P. Chaluvally-Raghavan, T. Miyake, C. V. Pecot, S.-J. Kim, H. J. Choi, F. Z. Bischoff, J. A. Mayer, L. Huang, A. M. Nick, C. S. Hall, C. Rodriguez-Aguayo, B. Zand, H. J. Dalton, T. Arumugam, H. J. Lee, H. D. Han, M. S. Cho, R. Rupaimoole, L. S. Mangala, V. Sehgal, S. C. Oh, J. Liu, J.-S. Lee, R. L. Coleman, P. Ram, G. Lopez-Berestein, I. J. Fidler, A. K. Sood, Hematogenous metastasis of ovarian cancer: Rethinking mode of spread. Cancer Cell 26, 77-91 (2014).
37. S. Reagan-Shaw, M. Nihal, N. Ahmad, Dose translation from animal to human studies revisited. FASEB J. 22, 659-661 (2008).
38. C. A. Pettaway, S. Pathak, G. Greene, E. Ramirez, M. R. Wilson, J. J. Killion, I. J. Fidler, Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin. Cancer Res. 2, 1627-1636 (1996).
39. R. Sanches, M. Kuiper, F. Penault-Llorca, B. Aunoble, C. D'Incan, Y.-J. Bignon, Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: Implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy. Cancer Gene Ther. 7, 707-720 (2000).